Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE)
Paepke S, Huober J, Sherko K, Eidtmann H, Untch M, Costa SD, Blohmer JU, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Jackisch C, Schneeweiss A, Denkert C, Engels K, Klare P, Fasching P, Burchardi N, Loibl S, Von Minckwitz G (2016)
Publication Type: Conference contribution
Publication year: 2016
Journal
Book Volume: 57
Pages Range: S98-S99
Authors with CRIS profile
Involved external institutions
Technische Universität München (TUM)
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Sana Kliniken AG
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss
Germany (DE)
Klinikum Südstadt Rostock
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Isarklinikum (Isar Kliniken GmbH)
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
HELIOS Kliniken
Germany (DE)
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Sana Kliniken AG
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss
Germany (DE)
Klinikum Südstadt Rostock
Germany (DE)
Kliniken Essen-Mitte
Germany (DE)
Isarklinikum (Isar Kliniken GmbH)
Germany (DE)
Universitätsklinikum Magdeburg A.ö.R.
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
HELIOS Kliniken
Germany (DE)
How to cite
APA:
Paepke, S., Huober, J., Sherko, K., Eidtmann, H., Untch, M., Costa, S.D.,... Von Minckwitz, G. (2016). Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE). (pp. S98-S99).
MLA:
Paepke, S., et al. "Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple negative or luminal B/HER2 normal breast cancer (GENEVIEVE)." 2016. S98-S99.
BibTeX: Download